ASTRAZEN
AstraZeneca Pharma India Limited
Healthcare · Drug Manufacturers - Specialty & Generic
Market price data is delayed by at least 15 minutes. Not for trading or investment decisions.
Fundamentals
Current Price
₹8,051
P/B Ratio
25.19
52W High
₹10,691
52W Low
₹7,551.5
Dividend Yield
41.00%
Profit Margin
9.23%
ROE
—
Debt / Equity
0.04
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Peer Comparison same NSE industry · top 10 by 1M return
Pharmaceuticals Drugsas of 8 Apr 2026 close
| Symbol | Company | Price | P/B | RSI | 1M Ret | ROE | D/E |
|---|---|---|---|---|---|---|---|
| ASTRAZENyou | AstraZeneca Pharma India Lim | ₹7,889.5 | 24.68 | 35.2 | -9.0% | — | 0.04 |
| BETA | Beta Drugs Limited | ₹1,451.7 | 3.32 | 68.6 | +35.2% | — | 0.66 |
| VENUSREM | Venus Remedies Limited | ₹961.1 | 2.16 | 56.4 | +27.1% | — | 0.02 |
| VALIANTORG | Valiant Organics Limited | ₹264.24 | 1.00 | 64.5 | +25.8% | — | 0.32 |
| SUVEN | Suven Life Sciences Limited | ₹169.06 | 13.35 | 74.2 | +24.4% | — | — |
| BLISSGVS | Bliss GVS Pharma Limited | ₹252.51 | 2.36 | 71.7 | +23.6% | — | 0.04 |
| BROOKS | Brooks Laboratories Limited | ₹71.73 | 1.83 | 61.7 | +22.7% | — | 0.07 |
| TAKE | Take Solutions Limited | ₹43.72 | 24.95 | 64.8 | +21.2% | — | — |
| SHILPAMED | Shilpa Medicare Limited | ₹403.7 | 3.24 | 83.5 | +21.2% | — | 0.24 |
| KOPRAN | Kopran Limited | ₹146.27 | 1.41 | 71.8 | +20.8% | — | 0.31 |
| BAFNAPH | Bafna Pharmaceuticals Limite | ₹123.76 | 3.21 | 65.5 | +15.7% | — | 0.36 |
Price Chart
Quarterly Results Last 4 quarters
| Metric | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|
| Revenue | ₹611.6 Cr | ₹559.1 Cr | ₹526.3 Cr | ₹477.5 Cr |
| Gross Profit | ₹245.2 Cr | ₹234.6 Cr | ₹230.9 Cr | ₹180.3 Cr |
| Operating Income | ₹41.0 Cr | ₹72.6 Cr | ₹64.5 Cr | ₹69.5 Cr |
| Net Income | ₹32.6 Cr | ₹54.2 Cr | ₹55.8 Cr | ₹58.3 Cr |
Values in INR Crore. Source: yfinance / NSE filings.
SWOT Analysis AI · news + fundamentals
SWOT not available.
Recent News Sentiment
No recent news for this stock.
Data sourced from yfinance and public NSE filings. Not investment advice.